New biomarkers and risk stratification in atrial fibrillation: simplicity and practicality matter

Helen R. Griffiths, Gregory Y.H. Lip

Research output: Contribution to journalEditorial

Abstract

Advances in our understanding of pathological mechanisms can inform the identification of various biomarkers for risk stratification, monitoring drug efficacy and toxicity; and enabling careful monitoring of polypharmacy. Biomarkers in the broadest sense refer to 'biological markers' and this can be blood-based (eg. fibrin D-dimer, von Willebrand factor, etc) urine-based (eg. thromboxane), or even related to cardiac or cerebral imaging(1). Most biomarkers offer improvements over clinical risk scores in predicting high risk patients - at least statistically - but usually at the loss of simplicity and practicality for easy application in everyday clinical practice. Given the various biomarkers can be informed by different aspects of pathophysiology (e.g. inflammation, clotting, collagen turnover) they can nevertheless contribute to a better understanding of underlying disease processes(2). Indeed, many age-related diseases share common modifiable underpinning mechanisms e.g. inflammation, oxidative stress and visceral adiposity.

LanguageEnglish
Pages1837-1839
Number of pages3
JournalCirculation
Volume130
Issue number21
Early online date7 Oct 2014
DOIs
Publication statusPublished - 18 Nov 2014

Fingerprint

Atrial Fibrillation
Biomarkers
Inflammation
Polypharmacy
Thromboxanes
Adiposity
von Willebrand Factor
Drug-Related Side Effects and Adverse Reactions
Oxidative Stress
Collagen
Urine

Keywords

  • antithrombotic agents
  • biomarkers
  • bleeding
  • Editorials
  • reactive oxygen species
  • stroke
  • thioredoxin

Cite this

Griffiths, Helen R. ; Lip, Gregory Y.H. / New biomarkers and risk stratification in atrial fibrillation : simplicity and practicality matter. In: Circulation. 2014 ; Vol. 130, No. 21. pp. 1837-1839.
@article{c0ce898a175344e39797c0290b7dcbfa,
title = "New biomarkers and risk stratification in atrial fibrillation: simplicity and practicality matter",
abstract = "Advances in our understanding of pathological mechanisms can inform the identification of various biomarkers for risk stratification, monitoring drug efficacy and toxicity; and enabling careful monitoring of polypharmacy. Biomarkers in the broadest sense refer to 'biological markers' and this can be blood-based (eg. fibrin D-dimer, von Willebrand factor, etc) urine-based (eg. thromboxane), or even related to cardiac or cerebral imaging(1). Most biomarkers offer improvements over clinical risk scores in predicting high risk patients - at least statistically - but usually at the loss of simplicity and practicality for easy application in everyday clinical practice. Given the various biomarkers can be informed by different aspects of pathophysiology (e.g. inflammation, clotting, collagen turnover) they can nevertheless contribute to a better understanding of underlying disease processes(2). Indeed, many age-related diseases share common modifiable underpinning mechanisms e.g. inflammation, oxidative stress and visceral adiposity.",
keywords = "antithrombotic agents, biomarkers, bleeding, Editorials, reactive oxygen species, stroke, thioredoxin",
author = "Griffiths, {Helen R.} and Lip, {Gregory Y.H.}",
year = "2014",
month = "11",
day = "18",
doi = "10.1161/CIRCULATIONAHA.114.012870",
language = "English",
volume = "130",
pages = "1837--1839",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "21",

}

New biomarkers and risk stratification in atrial fibrillation : simplicity and practicality matter. / Griffiths, Helen R.; Lip, Gregory Y.H.

In: Circulation, Vol. 130, No. 21, 18.11.2014, p. 1837-1839.

Research output: Contribution to journalEditorial

TY - JOUR

T1 - New biomarkers and risk stratification in atrial fibrillation

T2 - Circulation

AU - Griffiths, Helen R.

AU - Lip, Gregory Y.H.

PY - 2014/11/18

Y1 - 2014/11/18

N2 - Advances in our understanding of pathological mechanisms can inform the identification of various biomarkers for risk stratification, monitoring drug efficacy and toxicity; and enabling careful monitoring of polypharmacy. Biomarkers in the broadest sense refer to 'biological markers' and this can be blood-based (eg. fibrin D-dimer, von Willebrand factor, etc) urine-based (eg. thromboxane), or even related to cardiac or cerebral imaging(1). Most biomarkers offer improvements over clinical risk scores in predicting high risk patients - at least statistically - but usually at the loss of simplicity and practicality for easy application in everyday clinical practice. Given the various biomarkers can be informed by different aspects of pathophysiology (e.g. inflammation, clotting, collagen turnover) they can nevertheless contribute to a better understanding of underlying disease processes(2). Indeed, many age-related diseases share common modifiable underpinning mechanisms e.g. inflammation, oxidative stress and visceral adiposity.

AB - Advances in our understanding of pathological mechanisms can inform the identification of various biomarkers for risk stratification, monitoring drug efficacy and toxicity; and enabling careful monitoring of polypharmacy. Biomarkers in the broadest sense refer to 'biological markers' and this can be blood-based (eg. fibrin D-dimer, von Willebrand factor, etc) urine-based (eg. thromboxane), or even related to cardiac or cerebral imaging(1). Most biomarkers offer improvements over clinical risk scores in predicting high risk patients - at least statistically - but usually at the loss of simplicity and practicality for easy application in everyday clinical practice. Given the various biomarkers can be informed by different aspects of pathophysiology (e.g. inflammation, clotting, collagen turnover) they can nevertheless contribute to a better understanding of underlying disease processes(2). Indeed, many age-related diseases share common modifiable underpinning mechanisms e.g. inflammation, oxidative stress and visceral adiposity.

KW - antithrombotic agents

KW - biomarkers

KW - bleeding

KW - Editorials

KW - reactive oxygen species

KW - stroke

KW - thioredoxin

UR - http://www.scopus.com/inward/record.url?scp=84922480758&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.114.012870

DO - 10.1161/CIRCULATIONAHA.114.012870

M3 - Editorial

VL - 130

SP - 1837

EP - 1839

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 21

ER -